For the quarter ended December 2025, Privia Health (PRVA) reported revenue of $541.17 million, up 17.4% over the same period last year. EPS came in at $0.07, compared to $0.03 in the year-ago quarter.
The reported revenue represents a surprise of +4.06% over the Zacks Consensus Estimate of $520.06 million. With the consensus EPS estimate being $0.04, the EPS surprise was +67.87%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Privia Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Practice Collections: $868.6 million compared to the $889.58 million average estimate based on five analysts.
- Care Margin: $116.5 million versus $112.77 million estimated by five analysts on average.
- Platform Contribution: $55.1 million versus $54.7 million estimated by five analysts on average.
- Implemented Providers (as of end of period): 5,380 compared to the 5,324 average estimate based on three analysts.
- Value-Based Care Attributed Lives (as of end of period): 1.54 million versus 1.42 million estimated by three analysts on average.
View all Key Company Metrics for Privia Health here>>>
Shares of Privia Health have returned -0.5% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Privia Health Group, Inc. (PRVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
